LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,237
تعداد مقالات11,265
تعداد مشاهده مقاله79,763,227
تعداد دریافت فایل اصل مقاله116,356,591
Yaghoubi, Atieh, Asli, Samira, Parhizkar, Maryam, Mohammadpour, Maryam, Khorsand, Ali, Yousefi, Mehdi, Bamdad, Taravat, Amel Jamehdar, Saeid. (1401). Effect of the Previous History of the SARS-CoV-2 Infections on Antibody Levels among Sputnik V Vaccinated Healthcare Workers. سامانه مدیریت نشریات علمی, 20(1), 76-82. doi: 10.22034/iji.2023.93812.2260
Atieh Yaghoubi; Samira Asli; Maryam Parhizkar; Maryam Mohammadpour; Ali Khorsand; Mehdi Yousefi; Taravat Bamdad; Saeid Amel Jamehdar. "Effect of the Previous History of the SARS-CoV-2 Infections on Antibody Levels among Sputnik V Vaccinated Healthcare Workers". سامانه مدیریت نشریات علمی, 20, 1, 1401, 76-82. doi: 10.22034/iji.2023.93812.2260
Yaghoubi, Atieh, Asli, Samira, Parhizkar, Maryam, Mohammadpour, Maryam, Khorsand, Ali, Yousefi, Mehdi, Bamdad, Taravat, Amel Jamehdar, Saeid. (1401). 'Effect of the Previous History of the SARS-CoV-2 Infections on Antibody Levels among Sputnik V Vaccinated Healthcare Workers', سامانه مدیریت نشریات علمی, 20(1), pp. 76-82. doi: 10.22034/iji.2023.93812.2260
Yaghoubi, Atieh, Asli, Samira, Parhizkar, Maryam, Mohammadpour, Maryam, Khorsand, Ali, Yousefi, Mehdi, Bamdad, Taravat, Amel Jamehdar, Saeid. Effect of the Previous History of the SARS-CoV-2 Infections on Antibody Levels among Sputnik V Vaccinated Healthcare Workers. سامانه مدیریت نشریات علمی, 1401; 20(1): 76-82. doi: 10.22034/iji.2023.93812.2260

Effect of the Previous History of the SARS-CoV-2 Infections on Antibody Levels among Sputnik V Vaccinated Healthcare Workers

Iranian Journal of Immunology
دوره 20، شماره 1، خرداد 2023، صفحه 76-82    اصل مقاله (551.47 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22034/iji.2023.93812.2260
نویسندگان
Atieh Yaghoubi1، 2؛ Samira Asli3؛ Maryam Parhizkar4؛ Maryam Mohammadpour4؛ Ali Khorsand5؛ Mehdi Yousefi6؛ Taravat Bamdad7؛ Saeid Amel Jamehdar* 2
1Antimicrobial Resistance Research Center, Mashhad University of Medical Science, Mashhad, Iran.
2Department of Microbiology and Virology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3Clinical Research Development Center, Akbar Hospital, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
4Hand Hygiene and Infection Control Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
5Department of Complementary and Chines Medicine, School of Persian and Complementary Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
6Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
7Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
چکیده
Background: Measuring the level of antibodies produced post-vaccination in response to the SARS-CoV-2 spike protein is considered a strategy for estimating the effectiveness of the COVID-19 vaccines.
Objective: To examine the antibody levels among the healthcare workers in different hospitals in Mashhad, Iran after receiving the second dose of Sputnik V.
Methods: In this study, we enrolled 230 healthcare workers for evaluating the Gam-COVID-Vac or Sputnik V after the second administration in different hospitals in Mashhad. Antibody levels of spike protein were quantitatively evaluated in a sample of 230 negative RT-PCR tests for the COVID-19 individuals. The analysis has been done based on an immunological assay using enzyme-linked immunosorbent assay (ELISA). The infection history of the subjects and their families was examined through their medical records.
Results: Our results demonstrated a significant association between a higher titer of IgG and a previous history of the COVID-19 infection (P<0.001). Moreover, the chance of detecting antibodies titer more than 50 AU/ml was 16.99 in these people which was significantly higher than in people without a history of infection pre-vaccination [%95CI: (7.38,39.12), P<0.001].
Conclusion: This result demonstrates that the efficacy of antibody production is related to the previous history of the SARS-CoV-2 infections. Ongoing monitoring of the level of antibody among vaccinated populations will help evaluating the effect of vaccines on humoral immunity status.
کلیدواژه‌ها
COVID-19؛ Gam-COVID-Vac؛ SARS-CoV-2؛ Sputnik V
مراجع
  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet. 2020;395(10223):497-506.
  2. Cyranoski D. Did pangolins spread the China coronavirus to people [Internet]. Heidelberg: Springer Nature; 2020.
  3. Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514-23.
  4. Organization WH. The COVID-19 candidate vaccine landscape. Available online:(accessed on 9 January 2021). 2020.
  5. Food, Administration D. COVID-19 Vaccines Authorized for Emergency Use. 2021.
  6. Soleimanpour S, Yaghoubi A. COVID-19 vaccine: where are we now and where should we go? Expert Review of Vaccines. 2021;20(1):23-44.
  7. van Tulleken C. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost. bmj. 2021;373.
  8. Mathieu E, Ritchie H, Ortiz-Ospina E, Roser M, Hasell J, Appel C, et al. A global database of COVID-19 vaccinations. Nature human behaviour. 2021:1-7.
  9. Jones I, Roy P. Sputnik V COVID-19 vaccine candidate appears safe and effective. The Lancet. 2021;397(10275):642-3.
  10. Ikegame S, Siddiquey MN, Hung C-T, Haas G, Brambilla L, Oguntuyo KY, et al. Qualitatively distinct modes of Sputnik V vaccine-neutralization escape by SARS-CoV-2 Spike variants. medRxiv. 2021.
  11. Ikegame S, Siddiquey M, Hung C-T, Haas G, Brambilla L, Oguntuyo K, et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Research Square. 2021:rs. 3. rs-400230.
  12. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311(5768):1770-3.
  13. Ingravallo F. Death in the era of the COVID-19 pandemic. The Lancet Public Health. 2020;5(5):e258.
  14. Cobey S, Larremore DB, Grad YH, Lipsitch M. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination. Nature Reviews Immunology. 2021;21(5):330-5.
  15. Al-Amri SS, Abbas AT, Siddiq LA, Alghamdi A, Sanki MA, Al-Muhanna MK, et al. Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Scientific reports. 2017;7:44875.
  16. Li Y-D, Chi W-Y, Su J-H, Ferrall L, Hung C-F, Wu T-C. Coronavirus vaccine development: from SARS and MERS to COVID-19. Journal of biomedical science. 2020;27(1):1-23.
  17. Keshvardoost S, Bahaadinbeigy K, Fatehi F. Role of telehealth in the management of COVID-19: lessons learned from previous SARS, MERS, and Ebola outbreaks. Telemedicine and e-Health. 2020;26(7):850-2.
  18. Du L, He Y, Zhou Y, Liu S, Zheng B-J, Jiang S. The spike protein of SARS-CoV—a target for vaccine and therapeutic development. Nature Reviews Microbiology. 2009;7(3):226-36.
  19. Du L, Zhao G, He Y, Guo Y, Zheng B-J, Jiang S, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007;25(15):2832-8.
  20. Sternberg A, Naujokat C. Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life sciences. 2020:118056.
  21. Hasan A, Al-Ozairi E, Al-Baqsumi Z, Ahmad R, Al-Mulla F. Cellular and Humoral Immune Responses in Covid-19 and Immunotherapeutic Approaches. ImmunoTargets and Therapy. 2021;10:63.
  22. Kyriakidis NC, López-Cortés A, González EV, Grimaldos AB, Prado EO. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines. 2021;6(1):1-17.
  23. Deming ME, Lyke KE. A ‘mix and match’approach to SARS-CoV-2 vaccination. Nature Medicine. 2021:1-2.
  24. Ghiasi N, Valizadeh R, Arabsorkhi M, Hoseyni TS, Esfandiari K, Sadighpour T, et al. Efficacy and side effects of Sputnik V, Sinopharm and AstraZeneca vaccines to stop COVID-19; a review and discussion. 2021.
  25. Saeed U, Uppal SR, Piracha ZZ, Khan AA, Rasheed A, Waheed A, et al. Evaluation of SARS-CoV-2 spike antibody levels among Sputnik V first dose vaccinated people in Pakistan: formulation of national anti-COVID-19 mass vaccination strategy. 2021.
  26. Chahla RE, Tomas-Grau RH, Cazorla SI, Ploper D, Pingitore EV, Lopez MA, et al. Past SARS-CoV-2 infection elicits a strong immune response after a single vaccine dose. medRxiv. 2021.
  27. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. New England Journal of Medicine. 2021;384(14):1372-4.
آمار
تعداد مشاهده مقاله: 838
تعداد دریافت فایل اصل مقاله: 568


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب